New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, has found that rheumatoid arthritis (RA) patients in sustained remission who stopped TNF inhibitors (TNFi) had significantly more flares and lower Boolean 2.0 remission rates compared with those who continued treatment.
Leave A Comment